Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | Director | September 30, 2019 | October 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date September 30, 2019 · Filed October 04, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.17 · Expires 2019-09-27 | Direct | 1,856 |
Reported balance
After 2019-09-30 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2019-09-30 · Grant · Acquired 1,856 · Balance 1,856 F3: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2020-03-06 | Direct | 4,500 |
Reported balance
Holding disclosure · report date 2019-09-30 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 4,500 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.90 · Expires 2023-03-06 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2019-09-30 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 7,500 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2027-09-15 | Direct | 6,396 |
Reported balance
Holding disclosure · report date 2019-09-30 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance 6,396 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.26 · Expires 2029-03-30 | Direct | 2,501 |
Reported balance
Holding disclosure · report date 2019-09-30 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 2,501 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 | Direct | 7,718 |
Reported balance
Holding disclosure · report date 2019-09-30 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance 7,718 F2: Except as otherwise provided in the award notice, this option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable in full as of the date of this report.
F2: Except as otherwise provided in the award notice, this option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
F3: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2019 Filed Oct 2, 2019 08:40 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,856 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001209191-19-051418 · doc4.xml · derivative · entry 7 VACCINEX, INC. · CIK 0001205922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,856 Underlying: Common Stock · 1,856 shares Expires 2019-09-27 F7 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 07:59 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,856 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001209191-19-051415 · doc4.xml · derivative · entry 6 VACCINEX, INC. · CIK 0001205922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,856 Underlying: Common Stock · 1,856 shares Expires 2019-09-27 F3 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable. Read SEC document |
| September 30, 2019 Filed Oct 4, 2019 11:36 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,856 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001209191-19-052508 · doc4a.xml · derivative · entry 6 VACCINEX, INC. · CIK 0001205922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,856 Underlying: Common Stock · 1,856 shares Expires 2019-09-27 F3 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable. Read SEC document |
| September 30, 2019 Filed Oct 4, 2019 11:22 UTC Amendment | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 1,856 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001209191-19-052507 · doc4a.xml · derivative · entry 7 VACCINEX, INC. · CIK 0001205922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,856 Underlying: Common Stock · 1,856 shares Expires 2019-09-27 F7 · price: Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the third quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all of such options are immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.